



**Genocea Biosciences, Inc.
to Present at the
2011 BIO International Convention**

CAMBRIDGE, MA, May 25, 2011/Businesswire/--Genocea Biosciences, Inc., a vaccine discovery and development company, announced today that Jessica Baker Flechtner, VP of Research, will present at the 2011 BIO International Convention, June 28, 2011, in Washington, D.C.

Her presentation is part of a session titled “*Next Generation HSV-2 Vaccines.*” She will present progress on the lead Genocea program, a therapeutic HSV-2 vaccine designed to elicit broad T and B cell response in persons infected with HSV-2.

About Genocea

Genocea Biosciences is a vaccine discovery and development company targeting major infectious diseases with high unmet medical needs, in which T cell responses help confer protection. The company’s transformational discovery platform mines the natural immune response across diverse human populations in a way that radically reduces the risk, cost and time associated with antigen discovery. Genocea is currently developing vaccines for herpes simplex virus type-2 (therapeutic and prophylactic), a sexually transmitted disease affecting roughly 15 percent of the U.S. population; *Chlamydia trachomatis*, a sexually transmitted disease agent causing an estimated 90 million cases worldwide; *Streptococcus pneumoniae*, the leading killer of children under the age of 5 worldwide; and *Plasmodium falciparum* (malaria), of which there are more than 100 million cases globally. Visit www.genocea.com for more information.

CONTACT: Chip Clark, President and CEO, Genocea Biosciences +1.617.876.8191